GLUCAGON LAWSUIT WHITEPAPER
About Glucagon Lawsuit
Eli Lilly and Company voluntarily recalled lot D239382D, expiration April 2022 of their Glucagon Emergency Kit for Low Blood Sugar on September 25, 2021. The affected lot number and expiration date can be found on the label of the kit and on the vial.
Lilly recalled the lot because of a product complaint that the vial was in liquid form instead of powder form. Lilly’s investigation indicated that the liquid in the vial could be related to the manufacturing process. Glucagon is a hormone that is taken to control blood sugar levels in the body. The drug is taken by diabetes patients to treat very low blood sugar (severe hypoglycemia).
Eli Lilly announced that there was a report that one patient experienced seizures. Therefore, the drug was not potent enough and made it ineffective.
Eli Lilly is facing multiple lawsuits for the alleged manufacturing defects.
Glucagon Associated Injuries
The injuries associated with this drug include:
- Neurological damage
Glucagon Status of Litigation
Because the litigation is in the early stages, there Is currently no MDL. There have been no verdicts or known settlements at this time.
The current manufacturer in the lawsuit is Eli Lilly & Co.